Listar por autor "Yamabe, Takaharu"

Mostrando ítems 1-2 de 2

Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

Berenbaum, Francis; Blanco García, Francisco J; Guermazi, Ali; Miki, Kenji; Yamabe, Takaharu; Viktrup, Lars; Junor, Rod; Carey, William; Brown, Mark T.; West, Christine R.; Verburg, Kenneth M. (BMJ, 2020-03-31)

[Abstract] Objective. Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in a study with 24-week treatment and 24-week safety follow-up. Methods. This double-blind, ...
Subcutaneous tanezumab for osteoarthritis: is the early improvement in pain and function meaningful and sustained?

Berenbaum, Francis; Langford, R.; Perrot, S.; Miki, Kenji; Blanco García, Francisco J; Yamabe, Takaharu; Isogawa, N.; Junor, Rod; Carey, William; Viktrup, Lars; West, Christine R.; Brown, Mark T.; Verburg, Kenneth M. (Wiley, 2021-03-16)

[Abstract] Background: To evaluate if early improvements in pain and function with subcuta-neous tanezumab are meaningful and sustained over 24 weeks. Methods: Patients with moderate- to- severe osteoarthritis (hip or ...